Primary sclerosing cholangitis: a review and update on therapeutic developments.
about
Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liverMicro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography.Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapiesCholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitisCharacterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitisAssociation between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis.Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.Lipopolysaccharide (LPS)-Induced Biliary Epithelial Cell NRas Activation Requires Epidermal Growth Factor Receptor (EGFR).Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling.Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing CholangitisETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A.Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.Role of the microbiota and antibiotics in primary sclerosing cholangitis.Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-cell Receptor-positive Cells and Pathogenesis of Cholestatic Liver Disease.Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?).Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.Primary sclerosing cholangitis: A review and update
P2860
Q26766699-CF2C702B-C2D0-4557-9F11-62022182AA5AQ30560951-127B7814-8F45-4E74-9506-FA53E8F25213Q31170968-A9D4B0FE-4AD7-4F22-BCC1-7DA641F28FA6Q34206508-AE1C13E0-D6BC-41FF-9350-CAF18CD063A6Q34287861-B5E648E1-5723-4109-BCB3-6BBBE30A2DAAQ34416616-ABFF4FBB-4909-411A-BEB8-7D043736DBB5Q34479345-072E6FD9-1665-4189-B20C-61C7AC0D983DQ35615198-A07E7859-736D-407F-A48B-C28EF59F07DFQ35855133-856C8656-54CC-4984-BAE3-7F9C2A191DBAQ37206473-380C0955-54C8-4EB2-9A81-0EA6C0CACBE4Q38717030-CDE7F5A3-C126-4AA5-A0E3-0FEB2AC0DD9EQ39177947-9410367E-E20C-4940-9589-D74E2AA63F63Q42174395-DA0FA78F-D192-418A-9E09-D5231B247C9EQ48331749-53246E09-843A-46F1-96E8-346838637DB9Q49565626-5548462D-A90A-4402-B5C5-73911ED2F84DQ49896566-DA532A95-09E1-497A-96BB-06C6E3307CE3Q55058073-0E8ABCE4-81B6-4386-82E6-E9A9183E3FEDQ55497458-A17E5DD1-6A03-46F2-84DD-482740796A08Q57124621-EC2D6795-B271-4BB3-8A14-A8B1CB331DC7
P2860
Primary sclerosing cholangitis: a review and update on therapeutic developments.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Primary sclerosing cholangitis: a review and update on therapeutic developments.
@en
type
label
Primary sclerosing cholangitis: a review and update on therapeutic developments.
@en
prefLabel
Primary sclerosing cholangitis: a review and update on therapeutic developments.
@en
P2860
P356
P1476
Primary sclerosing cholangitis: a review and update on therapeutic developments.
@en
P2093
James H Tabibian
Keith D Lindor
P2860
P304
P356
10.1586/EGH.12.80
P577
2013-02-01T00:00:00Z